We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
arGEN-X Opens new R&D Facility in Flanders for Discovery and Development of Therapeutic Antibodies
News

arGEN-X Opens new R&D Facility in Flanders for Discovery and Development of Therapeutic Antibodies

arGEN-X Opens new R&D Facility in Flanders for Discovery and Development of Therapeutic Antibodies
News

arGEN-X Opens new R&D Facility in Flanders for Discovery and Development of Therapeutic Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "arGEN-X Opens new R&D Facility in Flanders for Discovery and Development of Therapeutic Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

arGEN-X BV has announced that it has opened a new R&D subsidiary in Flanders – arGEN-X BVBA.

The facility is supported by a €1.3 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) and is intended to become a center of excellence dedicated to the discovery and development of novel therapeutic antibodies based on arGEN-X’ SIMPLE Antibody™ platform.

The facility will operate under arGEN-X’ CSO Prof. Dr. Hans de Haard, and CDO Dr. Torsten Dreier, who have already attracted an experienced international core team of antibody discovery and development as well as project management experts.

Among those recently appointed is Dr Michael Saunders, who has joined arGEN-X as Senior Director Targets & Programs, bringing important relevant experience from within GlaxoSmithKline in target identification and project management.

Under this leadership, the Company is in the process of building an international team of around 25 leading antibody scientists to be based at this facility.

Prof. Dr. Hans de Haard, CSO of arGEN-X, commenting on this announcement said: “We have chosen to locate our R&D facility in what is the heart of the Benelux Biotech cluster and in a region with well-established infrastructure and expertise from which arGEN-X can draw. We are grateful to the Flemish government for providing a grant to help facilitate our move and are progressing towards building a world-leading antibody discovery and development capability. We are confident that we can create a center of excellence in Flanders, which will serve as a magnet to some of the best antibody talents globally who will be attracted by the clear potential of arGEN-X’ SIMPLE Antibody™ platform.”
Advertisement